TGD001

About TargED Biopharmaceuticals

TargED Biopharmaceuticals is a private, clinical-stage biotech focused on revolutionizing thrombosis treatment with its targeted enzyme delivery platform. Its lead asset, TGD001, is a novel biologic designed to break down blood clots irrespective of their composition and is currently in Phase 1 development for immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS). The company has strong academic roots, experienced leadership with prior success in the thrombosis space (Caplacizumab), and has secured significant venture funding, totaling over €60 million, to advance its pipeline.

About TargED Biopharmaceuticals

TargED Biopharmaceuticals is a private, clinical-stage biotech focused on revolutionizing thrombosis treatment with its targeted enzyme delivery platform. Its lead asset, TGD001, is a novel biologic designed to break down blood clots irrespective of their composition and is currently in Phase 1 development for immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS). The company has strong academic roots, experienced leadership with prior success in the thrombosis space (Caplacizumab), and has secured significant venture funding, totaling over €60 million, to advance its pipeline.

Therapeutic Areas